Zhu, M., Madia, P., Crawford, A., Brouwer‐Visser, J., Krueger, P., Haber, L., . . . Retter, M. W. Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer. Wiley.
Chicago Style (17th ed.) CitationZhu, Min, et al. Translational Findings Support Regimen Selection for First‐in‐human Study of Ubamatamab (MUC16 × CD3 Bispecific Antibody) in Patients with Recurrent Ovarian Cancer. Wiley.
MLA (9th ed.) CitationZhu, Min, et al. Translational Findings Support Regimen Selection for First‐in‐human Study of Ubamatamab (MUC16 × CD3 Bispecific Antibody) in Patients with Recurrent Ovarian Cancer. Wiley.
Warning: These citations may not always be 100% accurate.